Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allergan receives final approval for Inamed acquisition
Allergan expects to complete its exchange offer for the outstanding shares of Inamed common stock on March 10, 2006, the currently scheduled expiration time for the exchange offer.
Allergan expects to complete its exchange offer for the outstanding shares of Inamed common stock on March 10, 2006, the currently scheduled expiration time for the exchange offer.
The company has identified a vaccine as well as a passive immunotherapy with a selected monoclonal antibody which was highly active in animal models for Alzheimer’s disease. Both
Of the 49 patients who completed the study, 61% experienced nocturnal acid breakthrough (NAB) while treated with Zegerid compared to 92% who experienced NAB while being treated with
Ventiv will also provide Boehringer Ingelheim with a full suite of sales and marketing services to support this expanded sales effort. Boehringer Ingelheim, headquartered in Ingelheim, Germany, operates
According to the company, the letter cites several deficiencies in the application, including observations resulting from an FDA inspection of the contract laboratory employed by Impax to perform
Ventavis is approved and marketed in the US for the treatment of pulmonary arterial hypertension (PAH), a highly debilitating and potentially fatal disease characterized by high blood pressure
Emisphere’s eligen technology makes it possible to orally deliver a therapeutic molecule without altering its chemical form or biological integrity. The delivery technology is based on the use
Under the agreement, Valeant collected $28 million of a total of $34 million agreed to be paid in settlement of the dispute. Valeant expects Serbia to pay the
In patients who received two doses of HuMax-CD20, 77% achieved a 20% improvement in the number of swollen and tender joints. There were three dose levels tested in
BSI-201 is the first of a new class of cancer therapies that selectively induces tumor cell death by inhibiting enzyme function central to tumor survival. The drug is